Atea Pharmaceuticals (AVIR) Operating Income (2019 - 2026)

Atea Pharmaceuticals' Operating Income history runs 8 years deep, the most recent figure standing at -$48.0 million for Q1 2026.

• In Q1 2026, Operating Income fell 22.97% year-over-year to -$48.0 million; the TTM figure through Mar 2026 stood at -$189.9 million (down 17.06% YoY), while the FY2025 annual figure was -$180.9 million, up 6.25% from the prior year.
• Operating Income was -$48.0 million for Q1 2026 at Atea Pharmaceuticals, up from -$54.9 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$16.3 million in Q3 2022 to a low of -$69.8 million in Q1 2024.
• Historically, Operating Income has averaged -$42.2 million across 5 years, with a median of -$41.3 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Operating Income sank 471.76% in 2022, then surged 44.07% in 2025.
• A 5-year view of Operating Income shows it stood at -$39.9 million in 2022, then declined by 16.73% to -$46.6 million in 2023, then increased by 16.2% to -$39.0 million in 2024, then slumped by 40.76% to -$54.9 million in 2025, then gained by 12.61% to -$48.0 million in 2026.
• The last three Operating Income figures came in at -$48.0 million (Q1 2026), -$54.9 million (Q4 2025), and -$45.6 million (Q3 2025), per Business Quant data.